Charles Schwab Investment Management Inc. Grows Position in Surmodics, Inc. (NASDAQ:SRDX)

Charles Schwab Investment Management Inc. boosted its holdings in Surmodics, Inc. (NASDAQ:SRDX) by 1.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 117,904 shares of the company’s stock after buying an additional 1,593 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.82% of Surmodics worth $4,669,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. New York State Common Retirement Fund grew its stake in shares of Surmodics by 12.4% in the fourth quarter. New York State Common Retirement Fund now owns 19,544 shares of the company’s stock worth $774,000 after acquiring an additional 2,162 shares during the period. Principal Financial Group Inc. boosted its holdings in Surmodics by 17.5% in the fourth quarter. Principal Financial Group Inc. now owns 36,061 shares of the company’s stock worth $1,428,000 after purchasing an additional 5,365 shares during the last quarter. Rhumbline Advisers grew its position in Surmodics by 4.4% in the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock worth $802,000 after purchasing an additional 861 shares during the period. R Squared Ltd purchased a new stake in Surmodics during the 4th quarter valued at $55,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Surmodics by 22.1% during the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after buying an additional 1,255 shares during the period. Institutional investors own 96.63% of the company’s stock.

Surmodics Price Performance

Shares of Surmodics stock opened at $30.91 on Wednesday. The stock’s fifty day moving average is $33.24 and its 200 day moving average is $36.91. Surmodics, Inc. has a one year low of $25.17 and a one year high of $42.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 4.29 and a current ratio of 5.45. The stock has a market cap of $441.89 million, a P/E ratio of -30.60 and a beta of 1.19.

Surmodics (NASDAQ:SRDX) last posted its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 4.39% and a negative net margin of 11.48%. Sell-side analysts anticipate that Surmodics, Inc. will post 0.2 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on SRDX shares. StockNews.com began coverage on Surmodics in a report on Monday, February 3rd. They issued a “hold” rating for the company. Lake Street Capital upgraded Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Friday, March 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Thursday, January 30th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $50.00.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).